Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375103 | 1.00 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL2851129 | 1.00 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL4628706 | 0.89 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL1709762 | 0.89 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL4628700 | 0.89 | KMT2A (0.58) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL18395173 | 0.87 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL18395170 | 0.87 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL18395611 | 0.87 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL18395608 | 0.87 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNATDP1MEN1 | |
| SCHEMBL3781378 | 0.86 | KMT2A (0.47) | KMT2ASMN1; SMN2LMNATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101180278-A | 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | CN | claimed |
| EP-0684944-B1 | COUPLING PRODUCT OBTAINED FROM HYSTAMINE AND AN AMINO ACID | EXSYMOL SA (MC) | 2001-07-25 | — | — | EP | claimed |
| US-5792784-A | A PSEUDO-DIPEPTIDE PRODUCT WHICH IS HISTAMINE OR METHYL-SUBSTITUTED HISTAMINE COUPLED WITH A AMINO ACID; USED IN THERAPEUTICAL, COSMETOLOGICAL APPLICATIONS AND TREATS VISION DEFECT | Babizhayev, Marc (SU) | 1998-08-11 | — | — | US | claimed |
| CN-113845485-B | Amino acid derivative and preparation method and application thereof | 湖南中医药大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-112824423-B | Chiral ferrocenylphosphine-indolylaminophosphine ligand and preparation method and application thereof | 中国科学院大连化学物理研究所（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-112824422-B | Chiral ferrocene-indole diphosphine ligand as well as preparation method and application thereof | 中国科学院大连化学物理研究所（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2017222083-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | WO | disclosed |
| EP-1386901-B1 | Method for producing an optically active beta-amino acid | TAKASAGO PERFUMERY CO LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-1624052-B1 | Process for the production of beta-amino acids with the use of acylase | AJINOMOTO KK (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-1624052-B1 | Process for the production of beta-amino acids with the use of acylase | AJINOMOTO KK (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-20050065366-A1 | Method for producing optically active beta-phenylalanine compounds | AJINOMOTO CO., INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1487990-A2 | PROCESS FOR PREPARING OPTICALLY ACTIVE BETA-AMINOCARBOXYLIC ACIDS FROM RACEMIC N-ACYLATED BETA-AMINOCARBOXYLIC ACIDS | Degussa AG (DE) | 2004-12-22 | — | — | EP | disclosed |
| EP-1484314-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE BETA-PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003080854-A2 | PROCESS FOR PREPARING OPTICALLY ACTIVE BETA-AMINOCARBOXYLIC ACIDS FROM RACEMIC N-ACYLATED BETA-AMINOCARBOXYLIC ACIDS | DEGUSSA AG (DE) | 2003-10-02 | — | — | WO | disclosed |
| US-6399787-B1 | TRANSITION METAL COMPLEX | PENN STATE RESEARCH FOUNDATION | 2002-06-04 | — | — | US | disclosed |
| WO-1999059721-A1 | CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5792784-A | A PSEUDO-DIPEPTIDE PRODUCT WHICH IS HISTAMINE OR METHYL-SUBSTITUTED HISTAMINE COUPLED WITH A AMINO ACID; USED IN THERAPEUTICAL, COSMETOLOGICAL APPLICATIONS AND TREATS VISION DEFECT | Babizhayev, Marc (SU) | 1998-08-11 | — | — | US | disclosed |
| CN-1098404-A | Inhibitors of HIV protease as the treatment AIDS | LILLY CO ELI (US) | 1995-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065366-A1 | Method for producing optically active beta-phenylalanine compounds | PAH, NPEPPS, DNPEP | KMT2A 2037/4885SMN1; SMN2 2285/4885LMNA 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.